News

Jill Dietz, MD, FACS, a nationally recognized breast surgeon and leader in the development of innovative, recently joined Allegheny Health Network Cancer Institute.

David L. Bartlett, MD, a renowned cancer researcher and clinician specializing in advanced surgical treatments for abdominal cancers, has reopened his Pittsburgh practice.

In the phase 3 FOCUS study, a positive result for a secondary end point was observed with melphalan hydrochloride for injection in patients with liver-dominant metastatic ocular melanoma.

ST101, an agent being investigated in a phase 1/2 clinical trial, has been granted fast track designation from the FDA for the treatment of patients with glioblastoma multiforme.

Navel G. Daver, MD, discusses the molecular characteristics of acute myeloid leukemia, agents available for the treatment of mutated acute myeloid leukemia, and how to potentially improve treatment in the future.

The post-marketing requirements for duvelisib are no longer necessary, according to the FDA, and the agent has been withdrawn from the United States market for the treatment of patients with relapsed or refractory follicular lymphoma.

Shaakir Hasan, DO, discusses for potential reasons for continuing racial disparities in bladder cancer despite years of evidence of the issue.

In an interview with Targeted Oncology, James M. Foran, MD discussed how recent research has caused a paradigm shift in AML, and which ongoing clinical trials have the potential to change treatment in the near future.

Pembrolizumab for stage IIB or IIC melanoma has been granted approval by the FDA.

In the phase 3 ARASENS study, the use of darolutamide with docetaxel and androgen deprivation therapy demonstrated an overall survival advantage for patients with metastatic hormone-sensitive prostate cancer.

The device is meant to not only target metastatic bone lesions, but also promote the growth of healthy bone.

Luspatercept-aamt for the treatment of anemia in adult patients with non-transfusion dependent beta thalassemia is on track to receive an FDA approval indication.

Elisabetta Abruzzese, MD of S. Eugenio Hospital, discusses the management of pregnancy in patient with chronic myeloid leukemia.

The incidence of adverse events appeared to increase when bendamustine was added to venetoclax for the treatment of patients with released or refractory chronic lymphocytic leukemia

In an interview with Targeted Oncology, lead author Xichun Hu, MD, PhD, discussed A166 and its impact on HER2-positive breast cancer.

In the phase 3 IMforte clinical trial, researchers are exploring lurbinectedin and atezolizumab as induction and maintenance therapy for patients with extensive-stage small cell lung cancer.

Since the start of the Oncology Care Model program in 2016, Florida Cancer Specialists and Research Institute has saved Medicare $140 million.

With an orphan drug designation from the FDA, INBRX-109 may be on track to become the first FDA-approved treatment for chondrosarcoma.

Zai Lab has announced new findings from the phase 3 PRIME trial showing efficacy in progression-free survival in patients with platinum-sensitive ovarian cancer.

The combination elicited a complete response in patient with cervical cancer and a partial response in a patient with ovarian cancer.

The FDA has decided not to approve plinabulin with granulocyte colony-stimulating factor for the prevention of chemotherapy-induce neutropenia until further research is conducted.

Thomas Powles, MD, MBBS, MRCP, discusses the safety profile of enfortumab vedotin in urothelial cancers as observed in the phase 3 urothelial cancerstrial.

The approval is based on the phase 2 PLEAIDES study, which found the agent had an ORR of 84.8%, with 82.5% of patients still responding after 9 months.

Here is a look back FDA happenings from November 2021.

The FDA has extended the review period of the new drug application for pacritinib as treatment of patients with myelofibrosis and severe thrombocytopenia.

Dana Chase, MD, discusses frontline therapy options for patients with advanced ovarian cancer.

Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.

KB-0742 is currently being evaluated in a phase 1/2 clinical trial. The terminal half-life was found to be 24 hours.

Findings from the phase 3 OlympiA led to the filing of a supplemental new drug application for olaparib as adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer.

In an interview with Targeted Oncology, Ruben Niesvizky, MD, discussed current efficacy outcomes in multiple myeloma and how the introduction of the car-BIRD regimen may improve upon them.